Ocular Therapeutix (NSDQ:OCUL) yesterday announced the commercial launch of its Dextenza ophthalmic insert in the U.S.
Dextenza is an ocular insert that is designed to release 0.4 mg of dexamethasone to relieve pain after ophthalmic surgery. It can deliver drugs for up to 30 days after treatment in a physician’s office.
The Bedford, Mass.-based company won reimbursement from the Centers for Medicare & Medicaid Services for the insert in May and the initial launch is supported by the activation of the company’s C-code.
“We are extremely proud to be bringing Dextenza to market in the U.S.,” president & CEO Antony Mattessich said in a press release. “With reimbursement solidified through a unique C-code, the addition of inflammation to our label, and our direct, highly-experienced commercial team in place, we believe we are well-prepared for the launch of Dextenza. Dextenza represents a novel new treatment option that we believe offers significant value to both patients and physicians and we are excited for its potential in the market.”
Ocular Therapeutix said that the launch of Dextenza will initially focus on the two million cataract procedures that are performed annually through Medicare Part B, the market where the device has full reimbursement established following the effectiveness of C-code and pass-through payment status.
